Editor's Page

The goal of this supplement is to provide a clearer perspective of the impact of AML upon the health care system, as well as the benefit of an AML clinical pathway.
Making the transition from fee-for-service reimbursement to value-based models of care and payments will be slow and difficult.
It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future.
Together, the articles in this issue emphasize the continued importance of not getting so carried away with technology, pre-approved plans, or theoretically ideal outcomes that the human aspect of medical care and care providers is lost.
Collectively, this issue of JCP presents how market dynamics are changing in relation to oncology practices, what providers are doing to evolve with these changes, and how clinical pathways are advancing these changes to achieve better care for patients.
As another year draws to a close, I look back on the work produced by Journal of Clinical Pathways with pride. But it is still important to keep our focus on what’s next.
New developments within the parameters of clinical pathways and value-based care offer many possibilities, and the current issue of Journal of Clinical Pathways offers a wide scope of where the field stands.
Medicine changes rapidly, but you can always count on Journal of Clinical Pathways for the latest information on value-based care.
For those of us at Journal of Clinical Pathways, September marks our Clinical Pathways Congress, held the weekend of September 8 in Washington, DC. Although the Congress may be our primary focus, it is certainly not the only iron we have in the fire.
Our annual Clinical Pathways Congress (CPC) will be held in Washington, DC, over the second weekend in September, and we hope to see many of our readers there. We have reached an exciting moment in clinical pathways development.